

# Soldano Ferrone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8570171/publications.pdf>

Version: 2024-02-01

206  
papers

14,088  
citations

15466

65  
h-index

24179

110  
g-index

220  
all docs

220  
docs citations

220  
times ranked

17193  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
2	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. <i>Frontiers in Veterinary Science</i> , 2022, 9, 803093.	0.9	4
3	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2022, 8, 462.	3.4	22
4	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. , 2022, 10, e004115.		9
5	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. <i>Pathology and Oncology Research</i> , 2022, 28, 1610297.	0.9	5
6	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
7	Abstract 2812: CSPG4-specific CAR.CIK lymphocyte-based immunotherapy to eliminate HLA class I-defective melanoma tumors. <i>Cancer Research</i> , 2022, 82, 2812-2812.	0.4	0
8	Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. <i>Nature Communications</i> , 2022, 13, .	5.8	17
9	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	3.0	49
10	The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells. <i>Journal of Investigative Dermatology</i> , 2021, 141, 903-912.e4.	0.3	31
11	B7-H3: An Attractive Target for Antibody-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1227-1235.	3.2	162
12	The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. <i>Immunity</i> , 2021, 54, 132-150.e9.	6.6	52
13	B7-H3 targeted antibody-based immunotherapy of malignant diseases. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 587-602.	1.4	16
14	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021, 19, 17.	1.8	6
15	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. <i>Cancer Immunology Research</i> , 2021, 9, 441-453.	1.6	25
16	Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2837-2847.	3.2	17
17	Proteomic profile of melanoma cell-derived small extracellular vesicles in patients’ plasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12063.	5.5	38
18	Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 3141-3153.	3.2	45

#	ARTICLE	IF	CITATIONS
19	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. <i>Cells</i> , 2021, 10, 517.	1.8	20
20	Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 577-588.	1.9	40
21	A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3757-3771.	3.2	25
22	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. <i>Frontiers in Oncology</i> , 2021, 11, 598001.	1.3	3
23	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. <i>Cancers</i> , 2021, 13, 1674.	1.7	9
24	Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. <i>Hepatology</i> , 2021, 74, 550-565.	3.6	12
25	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. <i>Frontiers in Neuroscience</i> , 2021, 15, 662064.	1.4	80
26	Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. <i>Clinical Orthopaedics and Related Research</i> , 2021, 479, 1373-1382.	0.7	11
27	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 240.	3.5	3
28	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 1051.	3.4	25
29	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 1089-1101.	3.8	32
30	CD16 $\alpha$ -158 $\alpha$ valine chimeric receptor T cells overcome the resistance of KRAS $\alpha$ -mutated colorectal carcinoma cells to cetuximab. <i>International Journal of Cancer</i> , 2020, 146, 2531-2538.	2.3	15
31	<i>In vitro</i> elimination of epidermal growth factor receptor $\alpha$ -overexpressing cancer cells by CD32 $\alpha$ -chimeric receptor T cells in combination with cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2020, 146, 236-247.	2.3	30
32	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. <i>Scientific Reports</i> , 2020, 10, 92.	1.6	122
33	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 561390.	2.2	12
34	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 2659.	1.7	54
35	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019). <i>TJ ETQq</i> 1.1 0.784314 rgBT / 1.8 5	1.8	5
36	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , 2020, 26, 6321-6334.	3.2	24

#	ARTICLE	IF	CITATIONS
37	Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironmentâ€like Conditions. <i>Clinical Cancer Research</i> , 2020, 26, 4448-4453.	3.2	14
38	Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma. , 2020, 8, e000209.		12
39	Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. <i>Cell Communication and Signaling</i> , 2020, 18, 36.	2.7	47
40	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 255.	1.8	8
41	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5520-5533.	3.2	88
42	lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter. <i>IScience</i> , 2020, 23, 100835.	1.9	21
43	HLA Class I Antigen Processing Machinery Defects in Cancer Cellsâ€Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. <i>Methods in Molecular Biology</i> , 2020, 2055, 325-350.	0.4	26
44	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 4266-4281.	3.9	27
45	B7-H3-targeted Radioimmunotherapy of Human Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 4016-4038.	1.2	5
46	Novel <i>ANO5</i> mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia. <i>Head and Neck</i> , 2019, 41, 230-238.	0.9	7
47	Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 30-37.	2.0	20
48	Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. <i>Cancers</i> , 2019, 11, 1249.	1.7	5
49	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. <i>EBioMedicine</i> , 2019, 47, 33-43.	2.7	101
50	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , 2019, 25, 2644-2655.	3.2	56
51	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985549.	1.4	20
52	Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 223-249.	0.1	6
53	Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition. <i>Frontiers in Immunology</i> , 2019, 10, 224.	2.2	41
54	Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA Processing. <i>Clinical Cancer Research</i> , 2019, 25, 3673-3688.	3.2	54

#	ARTICLE	IF	CITATIONS
55	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	1.9	18
56	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. <i>Cancer Cell</i> , 2019, 35, 221-237.e8.	7.7	286
57	Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation. <i>Theranostics</i> , 2019, 9, 5739-5754.	4.6	36
58	IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2019, 229, S176.	0.2	5
59	Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. <i>Cancer Research</i> , 2019, 79, 1069-1084.	0.4	94
60	Constitutive and TNF $\alpha$ -inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	96
61	Defective HLA class I antigen processing machinery in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 999-1009.	2.0	68
62	Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1435138.	5.5	210
63	<sup>212</sup> Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. <i>Nuclear Medicine and Biology</i> , 2018, 58, 67-73.	0.3	40
64	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018, 77, 92-97.	0.8	7
65	Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury. <i>Journal of Clinical Oncology</i> , 2018, 36, 2453-2454.	0.8	2
66	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. , 2018, 6, 126.		40
67	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018, 9, 5097.	5.8	21
68	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , 2018, 53, 189-200.	4.3	80
69	Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform. <i>Immunologic Research</i> , 2018, 66, 584-604.	1.3	13
70	Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(âˆ’) Head and Neck Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2018, 8, 445.	1.3	50
71	<sup>212</sup> Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. <i>International Journal of Molecular Sciences</i> , 2018, 19, 925.	1.8	31
72	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 166-181.	0.9	10

#	ARTICLE	IF	CITATIONS
73	Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opinion on Biological Therapy, 2018, 18, 765-784.	1.4	13
74	Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. Blood, 2018, 132, 701-701.	0.6	6
75	Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 12015-12015.	0.8	1
76	B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nuclear Medicine and Biology, 2017, 47, 23-30.	0.3	52
77	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. OncoImmunology, 2017, 6, e1171447.	2.1	64
78	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Scientific Reports, 2017, 7, 2290.	1.6	99
79	Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Science Translational Medicine, 2017, 9, .	5.8	211
80	Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunological Investigations, 2017, 46, 221-238.	1.0	77
81	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery, 2017, 7, 1420-1435.	7.7	507
82	High Antigen Processing Machinery component expression in Langerhans cells from melanoma patientsâ€™ sentinel lymph nodes. Cellular Immunology, 2017, 320, 29-37.	1.4	5
83	ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Scientific Reports, 2017, 7, 9687.	1.6	17
84	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Letters, 2017, 409, 9-19.	3.2	48
85	Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. Journal of Immunological Methods, 2017, 450, 73-80.	0.6	33
86	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 707-716.	3.2	104
87	FCÎ³ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Frontiers in Immunology, 2017, 8, 457.	2.2	41
88	The Humoral Theory of Transplantation. Journal of Immunology Research, 2017, 2017, 1-3.	0.9	3
89	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 37646-37656.	0.8	23
90	Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. Oncotarget, 2017, 8, 113837-113846.	0.8	15

#	ARTICLE	IF	CITATIONS
91	Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients.. Journal of Clinical Oncology, 2017, 35, 6058-6058.	0.8	0
92	AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget, 2016, 7, 60872-60884.	0.8	8
93	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2016, 23, 609-617.	0.7	24
94	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clinical Cancer Research, 2016, 22, 5229-5237.	3.2	107
95	CSPG4 as a prognostic biomarker in chordoma. Spine Journal, 2016, 16, 722-727.	0.6	28
96	HLA class I downregulation is associated with enhanced NK cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. European Journal of Immunology, 2016, 46, 409-419.	1.6	31
97	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncology, 2016, 58, 52-58.	0.8	58
98	Antitumor Activity of BRAF Inhibitor and IFN $\gamma$ Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, 108, djv435.	3.0	35
99	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478.	3.2	168
100	Enhancement of anti-leukemia activity of NK cells <i>in vitro</i> and <i>in vivo</i> by inhibition of leukemia cell-induced NK cell damage. Oncotarget, 2016, 7, 2070-2079.	0.8	15
101	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget, 2016, 7, 7390-7402.	0.8	89
102	Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts. Oncology Research, 2015, 22, 117-121.	0.6	7
103	Melanoma initiating cells: where do we stand?. Melanoma Management, 2015, 2, 109-114.	0.1	5
104	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunology Research, 2015, 3, 936-945.	1.6	65
105	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Molecular Oncology, 2015, 9, 1982-1993.	2.1	22
106	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opinion on Therapeutic Targets, 2015, 19, 1339-1350.	1.5	22
107	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Research, 2015, 75, 2200-2210.	0.4	217
108	Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy. Journal of Biological Chemistry, 2015, 290, 26562-26575.	1.6	59

#	ARTICLE	IF	CITATIONS
109	Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. <i>Oncolmmunology</i> , 2015, 4, e1023975.	2.1	33
110	Ipilimumab in the treatment of metastatic melanoma: management of adverse events. <i>OncoTargets and Therapy</i> , 2014, 7, 203.	1.0	87
111	NK cells and T cells cooperate during the clinical course of colorectal cancer. <i>Oncolmmunology</i> , 2014, 3, e952197.	2.1	110
112	Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , 2014, 5, 5639.	5.8	109
113	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. , 2014, 2, 25.		112
114	Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. <i>Clinical Cancer Research</i> , 2014, 20, 6593-6604.	3.2	145
115	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. <i>Clinical Cancer Research</i> , 2014, 20, 3753-3762.	3.2	64
116	Dendritic cell maturation in HCV infection: Altered regulation of MHC class I antigen processing-presenting machinery. <i>Journal of Hepatology</i> , 2014, 61, 242-251.	1.8	14
117	HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker. <i>Neoplasia</i> , 2014, 16, 31-W15.	2.3	99
118	Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. <i>Gynecologic Oncology</i> , 2014, 132, 203-210.	0.6	40
119	T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2014, 20, 962-971.	3.2	95
120	Novel Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy to Eradicate Both Differentiated Cancer Cells and Cancer-Initiating Cells in Solid Tumors. <i>Seminars in Oncology</i> , 2014, 41, 685-699.	0.8	10
121	Therapeutic Monoclonal Antibodies: Introduction. <i>Seminars in Oncology</i> , 2014, 41, 556-558.	0.8	3
122	Programmed Cell Death Ligand 1 Expression in Osteosarcoma. <i>Cancer Immunology Research</i> , 2014, 2, 690-698.	1.6	182
123	Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4. <i>Journal of Immunology</i> , 2014, 192, 523-532.	0.4	97
124	Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP $\alpha$ 1 inhibitor in combination with topoisomerase i inhibitor or radiation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 953-961.	1.1	12
125	Detection of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 523-535.	0.4	16
126	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 230-230.	0.8	2



#	ARTICLE	IF	CITATIONS
127	Blocking the formation of radiation-induced breast cancer stem cells. <i>Oncotarget</i> , 2014, 5, 3743-3755.	0.8	92
128	Dose-seeking and efficacy study of combination BRAFi and high-dose IFN (HDI) for therapy of advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9110-TPS9110.	0.8	0
129	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9105-TPS9105.	0.8	0
130	Emerging BRAF inhibitors for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 431-443.	1.0	5
131	EGFR-mediated tumor immunoescape. <i>Oncolmmunology</i> , 2013, 2, e27215.	2.1	35
132	SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells. <i>Clinical Cancer Research</i> , 2013, 19, 798-808.	3.2	70
133	LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 1816-1826.	3.2	70
134	Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , 25-47.	0.1	4
135	Multidisciplinary Approach to Patient with Malignant Melanoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 887-900.	0.9	3
136	CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma. <i>Clinical Cancer Research</i> , 2012, 18, 5352-5363.	3.2	78
137	Melanoma Cells Inhibit NK Cell Functionsâ€”Letter. <i>Cancer Research</i> , 2012, 72, 5428-5429.	0.4	61
138	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 127, 420-425.	0.6	64
139	Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. <i>International Journal of Oncology</i> , 2012, 40, 965-974.	1.4	39
140	Targeting ALDHbright Human Carcinomaâ€”Initiating Cells with ALDH1A1-Specific CD8+ T Cells. <i>Clinical Cancer Research</i> , 2011, 17, 6174-6184.	3.2	148
141	CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 1148-1157.	1.5	145
142	Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma. <i>Veterinary Journal</i> , 2011, 190, e26-e30.	0.6	37
143	Association of IFN- $\gamma$ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines. <i>Clinical Cancer Research</i> , 2011, 17, 2668-2678.	3.2	67
144	Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4. <i>Cancer Research</i> , 2011, 71, 7410-7422.	0.4	54

#	ARTICLE	IF	CITATIONS
145	Hidden Immunotherapy Targets Challenge Dogma. <i>Science Translational Medicine</i> , 2011, 3, 99ps38.	5.8	12
146	Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 529-540.	2.0	77
147	Response to the letter to the editors by Ottaiano et al.: "Cetuximab-dependent ADCC in cancer: dream or reality?" <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1609-1610.	2.0	0
148	A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas. <i>Cancer Research</i> , 2010, 70, 3027-3033.	0.4	70
149	Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies. <i>Clinical Cancer Research</i> , 2010, 16, 11-20.	3.2	65
150	CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1496-1512.	3.0	148
151	Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 800-813.	3.2	295
152	Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. <i>Journal of Clinical Oncology</i> , 2010, 28, 4390-4399.	0.8	285
153	Functional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4. <i>Advances in Cancer Research</i> , 2010, 109, 73-121.	1.9	93
154	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1853-1862.	2.0	148
155	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. <i>Journal of Clinical Investigation</i> , 2009, 119, 1251-1263.	3.9	313
156	Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 197-206.	2.0	160
157	Anti-inflammatory biologic therapies and immune surveillance of melanoma. <i>Expert Review of Dermatology</i> , 2008, 3, 129-131.	0.3	0
158	Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature. <i>Cancer Research</i> , 2008, 68, 8066-8075.	0.4	91
159	Expression and prognostic significance of prothymosin- $\beta$ and ERp57 in human gastric cancer. <i>Surgery</i> , 2007, 141, 41-50.	1.0	93
160	Immune selective pressure and HLA class I antigen defects in malignant lesions. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 227-236.	2.0	102
161	Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3890-3895.	3.2	200
162	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. <i>Expert Review of Dermatology</i> , 2006, 1, 805-823.	0.3	5

#	ARTICLE	IF	CITATIONS
163	HLA Class I Antigen Down-regulation in Primary Laryngeal Squamous Cell Carcinoma Lesions as a Poor Prognostic Marker. <i>Cancer Research</i> , 2006, 66, 9281-9289.	0.4	165
164	The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells.. <i>Blood</i> , 2006, 108, 4550-4550.	0.6	1
165	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. <i>Oncogene</i> , 2005, 24, 4634-4644.	2.6	92
166	A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. <i>Journal of Immunological Methods</i> , 2005, 299, 139-151.	0.6	56
167	Human High Molecular Weight Melanoma-Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Enhancement of Immunogenicity of Anti-Idiotypic Monoclonal Antibody MK2-23 by Fusion with Interleukin 2. <i>Cancer Research</i> , 2005, 65, 6976-6983.	0.4	21
168	Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome. <i>Clinical Cancer Research</i> , 2005, 11, 2552-2560.	3.2	222
169	Classical and Nonclassical HLA Class I Antigen and NK Cellâ€“Activating Ligand Changes in Malignant Cells: Current Challenges and Future Directions. <i>Advances in Cancer Research</i> , 2005, 93, 189-234.	1.9	102
170	Immune Selection of Hot-Spot $\beta$ 2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy. <i>Journal of Immunology</i> , 2005, 174, 1462-1471.	0.4	96
171	Differential Immunogenicity of Two Peptides Isolated by High Molecular Weight-Melanoma-Associated Antigen-Specific Monoclonal Antibodies with Different Affinities. <i>Journal of Immunology</i> , 2005, 174, 7104-7110.	0.4	22
172	Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. <i>Journal of Cell Biology</i> , 2004, 165, 881-891.	2.3	133
173	Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. <i>Blood</i> , 2004, 103, 3122-3130.	0.6	102
174	Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance. <i>Critical Reviews in Immunology</i> , 2004, 24, 267-296.	1.0	167
175	The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction.. <i>Blood</i> , 2004, 104, 2948-2948.	0.6	0
176	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. <i>Cancer</i> , 2003, 97, 2203-2211.	2.0	35
177	$\beta$ 2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide. <i>Journal of Immunology</i> , 2003, 171, 1918-1926.	0.4	150
178	Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. <i>Clinical Cancer Research</i> , 2003, 9, 1721-7.	3.2	87
179	Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. <i>Clinical Cancer Research</i> , 2003, 9, 4043-51.	3.2	63
180	Changes in Serum Ganglioside and Antibody Levels in Soft Tissue Sarcoma. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0</i> <a href="#">rgBT /Overlock 10 Tf</a>	1.0	1

#	ARTICLE	IF	CITATIONS
181	Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon- $\gamma$ immunotherapy. <i>Cancer</i> , 2001, 92, 369-376.	2.0	155
182	TAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis. <i>International Journal of Cancer</i> , 2001, 95, 23-28.	2.3	70
183	Differential clinical significance of $\beta$ 3 expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. , 2000, 89, 153-159.		28
184	$\beta$ 3 expression on blood vessels and melanoma cells in primary lesions; differential association with tumor progression and clinical prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 314-318.	2.0	28
185	Structural Relatedness of Distinct Determinants Recognized by Monoclonal Antibody TP25.99 on $\beta$ 2-Microglobulin-Associated and $\beta$ 2-Microglobulin-Free HLA Class I Heavy Chains. <i>Journal of Immunology</i> , 2000, 165, 3275-3283.	0.4	49
186	Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells. <i>Journal of Experimental Medicine</i> , 1999, 190, 205-216.	4.2	98
187	Escape of Human Solid Tumors from T Cell Recognition: Molecular Mechanisms and Functional Significance. <i>Advances in Immunology</i> , 1999, 74, 181-273.	1.1	998
188	Specific Lysis of Melanoma Cells by Receptor Grafted T Cells is Enhanced by Anti-Idiotypic Monoclonal Antibodies Directed to the scFv Domain of the Receptor. <i>Journal of Investigative Dermatology</i> , 1999, 112, 744-750.	0.3	23
189	HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. <i>Trends in Molecular Medicine</i> , 1999, 5, 178-186.	2.6	321
190	Down-Regulation of HLA Class I Antigen-Processing Molecules in Malignant Melanoma. <i>American Journal of Pathology</i> , 1999, 154, 745-754.	1.9	239
191	Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. <i>Trends in Immunology</i> , 1995, 16, 487-494.	7.5	447
192	Radioimmuno-detection of Melanoma: Preliminary Results of a Prospective Study. <i>International Journal of Biological Markers</i> , 1986, 1, 47-54.	0.7	20
193	Distribution of a Cross-Species Melanoma-Associated Antigen in Normal and Neoplastic Human Tissues. <i>Journal of Investigative Dermatology</i> , 1985, 85, 340-346.	0.3	14
194	Analysis of the NIH Workshop Monoclonal Antibodies to Human Melanoma Antigens. <i>Hybridoma</i> , 1982, 1, 473-482.	0.9	16
195	HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA-A AND B ANTIGENS BEARING MOLECULES. <i>Transplantation</i> , 1982, 34, 18-23.	0.5	95
196	Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. <i>International Journal of Cancer</i> , 1981, 28, 293-300.	2.3	240
197	Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and) Tj ETQq1 1 0,784314 rgBT /Ovel	1.2	40
198	Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: Analysis of the role of Ia-like antigens with monoclonal antibodies. <i>Immunogenetics</i> , 1981, 12, 267-274.	1.2	57

#	ARTICLE	IF	CITATIONS
199	Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives. Arthritis and Rheumatism, 1980, 23, 265-272.	6.7	41
200	Sera from Volunteers Immunized by Planned Blood Transfusions as a Source of Dr Cytotoxic Typing Reagents. Immunological Investigations, 1979, 8, 93-106.	0.9	3
201	Structural polymorphism of human DR antigens. Nature, 1979, 279, 436-437.	13.7	66
202	The Major Portion of Rabbit Antibody to Serum HLA A9 Antigens is Directed to Allospecificity. Tissue Antigens, 1978, 12, 153-155.	1.0	1
203	Rabbit Complement in the Lymphocytotoxicity Test. Tissue Antigens, 1977, 9, 223-226.	1.0	14
204	Association of HL-A antigens and <sup>2</sup> 2-microglobulin at the cellular and molecular level. Immunogenetics, 1975, 2, 183-197.	1.2	55
205	Activation of the complement system by H-2 alloantisera: Differential susceptibility to lysis of thymocytes and lymphocytes. Immunogenetics, 1975, 2, 199-203.	1.2	1
206	Diversity of Extracellular Vesicles (EV) in Plasma of Cancer Patients. Physiology, 0, , .	4.0	0